anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
A technique for retaining the blind when administering supplies in a clinical trial, when the two treatments cannot be made identical. Supplies are prepared for Treatment A (active and indistinguishable placebo) and for Treatment B (active and indistinguishable placebo). Subjects then take two sets of treatment; either A (active) and B (placebo), or A (placebo) and B (active). (ICH E9) Dropout
== Principle == In the case of M13 filamentous phage display, the DNA encoding the protein of interest is inserted into the gene encoding either the minor (pIII) or the major (pVIII) coat protein. The modified coat protein gene and the rest of the phage genome is then introduced into E. coli bacteria, which produce phage virions with the relevant protein fragment as part of their outer coat phage and the DNA encoding for these proteins packaged inside the phage. The phages can then be selected using e.g. DNA or protein molecules immobilized on the surface of a microplate. Specifically, phages that display proteins that binds to those targets will remain attached, while others will be removed by washing. Those that remain can be eluted and amplified by bacterial infection. The repeated cycling of selection, elution and amplification is sometimes referred to as 'panning', in reference to the enrichment of a sample of gold by removing undesirable materials. Phage eluted in the final step can be sequenced to identify the selected proteins. During amplification step, additional mutations may be introduced into the genes encoding the proteins of interest, enabling a directed evolution protocol. Elution can be done combining low-pH elution buffer with sonification, which, in addition to loosening the peptide-target interaction, also serves to detach the target molecule from the immobilization surface. This ultrasound-based method enables single-step selection of a high-affinity peptide.
=== Cation exchange resins === Strong acid cation (SAC) resins: Composed of a polystyrene matrix with a sulphonate (SO3−) functional group. Used in softening or demineralization processes. Weak acid cation (WAC) resins: Composed of an acrylic polymer and carboxylic acid functional groups. Used to selectively remove cations associated with alkalinity.
Maureen Vevers. Chair of Governors, Askham Bryan College, York. For services to Further Education. Alexandra Ellen Vincent. Lately Chief Operating Officer, Arts and Humanities Research Council. For services to Research Funding. Suman Vohra. Vice Chair, Edinburgh Hindu Mandir and Cultural Centre. For services to the community in Edinburgh. Belinda Alison Voos. Lately Nurse Consultant in Paediatric Neurosurgery, Great Ormond Street Hospital for Children NHS Foundation Trust. For services to Paediatric Neurosurgical Nursing. Dorothy Helen Wagstaff. Founder, CASCAID. For services to Charity. David Walker. Chair of Trustees, Horizons Specialist Academy Trust. For services to Education. Susan Walker. Chief Commissioner, Girlguiding Scotland. For services to Young People. David Wallace. Senior Fleet Staff Engineer, Royal National Lifeboat Institution. For voluntary service to Maritime Safety. Lady (Julia Elizabeth) Walport (Dr. Julia Neild). Lately Trustee, The Amber Trust and Trustee, Ealing Youth Orchestra. For services to Young People and to Charity. Keith Norman Walton. Founder, Severnside Community Rail Partnership. For services to Urban Rail Transport in Bristol. John Ward. Chair, Charles and Elsie Sykes Trust. For services to Charity and to the community in Harrogate, North Yorkshire. Pamela Joan Ward. For services to the community in Whipsnade, Bedfordshire. William John Ward. For services to the community in the New Forest, Hampshire. Edward Charles Warner. Disability and Access Ambassador, Cabinet Office Disability Unit. For services to Disabled People.
== Career == After graduation, Baker did post-doctoral research in Richard D. Smiths' laboratory at Pacific Northwest National Laboratory (PNNL), and was later promoted to senior research scientist. In 2018, she began her academic career at North Carolina State University as associate professor, and moved to University of North Carolina at Chapel Hill in 2022. The scope of Baker's research involves both developing high throughput ion mobility–mass spectrometry (IMS–MS) systems and using these hybrid instruments to study biological and environmental systems. She was one of five researchers from the PNNL Interactive Omics Group who worked on the Structures for lossless ion manipulations (SLIM). The group received the R&D 100 Award for their effort on SLIM in 2017. She was also part of the PNNL team who helped with the commercialization of the Agilent 6560 Ion Mobility Quadrupole Time-of-Flight (IM–QTOF) Liquid Chromatography–Mass Spectrometer system. She is an expert in the research of perfluoroalkyl and polyfluoroalkyl substances (PFAS) analysis. She is the director of the Core of Advanced Platform Technologies Used for Remediation and Exploration (CAPTURE), the analytical branch of the PFAS Superfund Research Centre. She is named one of the "Worldwide Water Warriors" in 2017. Baker served as a member-at-large for education for the American Society for Mass Spectrometry from 2019 to 2020. She serves on the editorial board of Journal of the American Society for Mass Spectrometry, Journal of Proteome Research, International Journal of Mass Spectrometry, and Scientific Reports.
Sources: en.wikipedia.org
=== Features === The project led by MSRDC will observe international road design and safety standards, with an intelligent highway management system for traffic surveillance. The expressway is designed for a top speed of 150 km/h on plain terrain and 120 km/h on hilly terrain, even though the legal speed limit remains at 120 km/h for cars and 80 km/h for trucks, enforceable by CCTV cameras, making it the fastest road network in the country, which will cut down the travel time between the two cities to eight hours from the present 16-hour. The Super Communication Expressway will considerably contribute to the 6% to the national trunk and freight infrastructure. Nearly 36% of the state population will observe the Samruddhi Corridor as a substantial growth driver, putting a direct positive impact on their livelihood. The MSRDC has been authorized as a nodal agency, the New Town Development Authority (NTDA), for developing 19 new townships along the route, which will include state-of-the-art healthcare facilities, skill development centers, IT parks, and educational institutions. The expressway will pass through 3 wildlife sanctuaries, including a 29.6 km passage through the Katepurna Wildlife Sanctuary in Akola, 29.15 km through the Karanja-Sohol Black Buck Sanctuary in Washim, and 44.975 km through the Tansa Wildlife Sanctuary in Thane. The Mumbai–Nagpur Expressway has been envisioned to ensure zero fatalities, and will have CCTVs and free telephone booths at every 5 km interval in case of an emergency.
The Dutch sprinter Foekje Dillema was expelled from the 1950 national team after she refused a mandatory sex test in July 1950; later investigations revealed a Y-chromosome in her body cells, and the analysis showed that she was probably a 46,XX/46,XY mosaic female. In 1953, a human chimera was reported in the British Medical Journal. A woman was found to have blood containing two different blood types. Apparently this resulted from her twin brother's cells living in her body. A 1996 study found that such blood group chimerism is not rare. In 2002, an article in the New England Journal of Medicine described a woman, later identified as Karen Keegan, in whom tetragametic chimerism was unexpectedly identified after she underwent preparations for kidney transplant. Those preparations for the transplant required the patient and her immediate family to undergo histocompatibility testing, the result of which had suggested that she was not the biological mother of two of her three children. In 2002, Lydia Fairchild was denied public assistance in Washington state when DNA evidence appeared to show that she was not the mother of her children. A lawyer for the prosecution heard of the case of Karen Keegan in New England, and suggested the possibility to the defense, who were able to show that Fairchild, too, was a chimera with two sets of DNA, and that one of those sets could have produced the children. In 2009, singer Taylor Muhl's large torso birthmark was diagnosed as resulting from chimerism.
Life Length is a biotechnology company. Founded in 2010 by Stephen J. Matlin and Dr. María Blasco Marhuenda, the company provides telomere diagnostics as well as telomerase measurement. Life Length is Spain's only federally-accredited laboratory under CLIA. It has three main facilities, with offices in Madrid and laboratories located in Tres Cantos.
== Business, finance, and economics == Safety improvement plan, a plan for improving safety Sales incentive plan, a type of employee incentive program Securities information processor, the part of public infrastructure for disseminating market data in the United States Share Incentive Plan, a UK government approved employee plan Systematic investment plan, an investment strategy
== Chemistry == SR-17018 is variously described as a piperidinylbenzimidazolone, piperidine–benzimidazole, or N-benzyl piperidine 4-benzimidazolone derivative. It is structurally related to designer opioids such as brorphine.
Sources: en.wikipedia.org
Homestead: The Series is an American post-apocalyptic drama television series produced and distributed by Angel Studios on their Angel streaming platform. Based on the book series Black Autumn: A Post-Apocalyptic Saga, it picks up where the Homestead film left off. The film was released in December 2024 and the first two episodes of the series were released on Angel concurrently. Production of the remainder of season 1 resumed after the film was released and episode 3 premiered on November 26, 2025. The series follows a group of people who have gathered at wealthy prepper Ian Ross's compound in the Rocky Mountains in the aftermath of a nuclear attack on Los Angeles and subsequent nationwide blackout which cuts off nearly all electricity and communication. The first season chronicles the events in the two months after the attacks. After Ian is critically wounded, his wife Jenna tries to maintain control of the Homestead and carry out Ian's wishes as a power struggle develops between her and the military special forces soldiers who Ian invited to provide security for the Homestead compound. Refugees gather outside the gates of the Homestead and Jenna wrestles with whether and how to help them. Meanwhile, a force led by local government officials and FEMA operatives threatens to take over the Homestead and recruits local gangs and thugs to join them. The first season is composed of eight episodes. It has been renewed for a second season.
== Inventions == James Watt did not invent the steam engine, nor were his ideas on steam engine power inspired by a kettle lid pressured open by steam. Watt improved upon the already commercially successful Newcomen atmospheric engine (invented in 1712 by Thomas Newcomen) in the 1760s and 1770s, making certain improvements critical to its future usage; his new steam engine later gained huge fame as a result. Although the guillotine was named after the French physician Joseph-Ignace Guillotin, he neither invented nor was executed with this device. He died peacefully in his own bed in 1814. Rather, it was Guillotin's speech favoring beheadings over other forms of execution that led to the device being referred to as "La machine Guillotine" and later simply guillotine. Thomas Crapper did not invent the flush toilet. A forerunner of the modern toilet was invented by the Elizabethan courtier Sir John Harington in the 16th century, and in 1775 the Scottish mechanic Alexander Cumming developed and patented a design for a toilet with an S-trap and flushing mechanism. Crapper, however, did much to increase the popularity of the flush toilet and introduced several innovations in the late 19th century, holding nine patents, including one for the floating ballcock. Thomas Edison did not invent the light bulb.
=== Multisignature wallet === In contrast to simple cryptocurrency wallets requiring just one party to sign a transaction, multi-sig wallets require multiple parties to sign a transaction. Multisignature wallets are designed to increase security by requiring a predefined threshold of signatures from independent private keys to authorize any transaction.
CB03-154 is a Kv7.2 and Kv7.3 potassium channel opener which is under development for the treatment of amyotrophic lateral sclerosis (ALS), epilepsy, major depressive disorder, bipolar disorders, stroke, and pain in China. It is taken orally. The drug is said to have higher selectivity and stability compared to retigabine. CB03-154 is under development by Shanghai Zhimeng Biopharma. As of November 2025, it is in 2/3 clinical trials for ALS, phase 2 trials for epilepsy and major depressive disorder, phase 1 trials for bipolar disorders, and the preclinical research stage of development for stroke, whereas no recent development has been reported for pain.
The activity: A = λN. The amount of substance: n = N/NA. The mass: m = Mn = MN/NA. where NA = 6.02214076×1023 mol−1 is the Avogadro constant, M is the molar mass of the substance in kg/mol, and the amount of the substance n is in moles.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.